Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV

WEDNESDAY, Aug. 5, 2026 (HealthDay News) -- For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to once-daily oral bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) for maintaining HIV viral load suppression, according to a study published online July 29 in the New England Journal of Medicine.Jürgen K. Rockstroh, M.D., from the University Hospital Bonn in Germany, and colleagues conducted a phase 3, double-blind, randomized, active-controlled, noninferiority trial involving adults in 12 counties, in whom HIV-1 had been virologically suppressed for at least six months while they were receiving B/F/TAF, to examine the efficacy and safety of a switch to once-weekly oral ISL/LEN. A total of 607 participants were randomly assigned in a 1:1 ratio to receive ISL/LEN or to continue B/F/TAF for 96 weeks; for the alternative regimen, all received matched placebo.At 48 weeks, the researchers found that an HIV-1 RNA level of 50 copies/mL or higher was reported in no participants in the ISL/LEN group and one participant (0.3 percent) in the B/F/TAF group; an HIV-1 RNA level of less than 50 copies/mL was reported in 284 and 280 (93.4 and 92.4 percent, respectively). At 48 weeks, the mean change in the CD4+ T-cell count was −10 and −18 cells/µL with ISL/LEN and B/F/TAF, respectively. Due to adverse events in 2.0 and 1.7 percent of participants in the ISL/LEN and B/F/TAF groups, respectively, the trial regimen was discontinued; serious adverse events occurred in 5.3 and 4.6 percent, respectively."The first-ever weekly oral therapy for the treatment of HIV could offer welcome relief from the burden of life-long daily pill-taking for people living with HIV," senior author Chloe Orkin, M.B., B.Ch., from Queen Mary University of London, said in a statement. "This is especially important for people that are experiencing stigma and people with other HIV-associated health conditions who are taking multiple other tablets."Several authors disclosed ties to biopharmaceutical companies, including Gilead Sciences and Merck, which are developing islatravir-lenacapavir and funded the study.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV

Related Stories

Once-Weekly Pill Could Revolutionize HIV Treatment

Oral Microbiome Dysbiosis Linked to Symptomatic Hand Osteoarthritis

Active Combined Oral Contraceptive Pills Linked to Emotional Eating

FDA Approves Oral Utebzi Antibiotic for Complicated Urinary Tract Infections